

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6. (Canceled)

7. (Previously Presented) A liposomal formulation comprising:

- a) a liposome having an antineoplastic drug encapsulated therein; and
- b) an empty liposome, wherein said antineoplastic drug is a

camptothecin.

8. (Original) The liposomal formulation of claim 7, wherein said

camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

9. (Original) The liposomal formulation of claim 8, wherein said

camptothecin is topotecan.

10. (Previously Presented) A liposomal formulation comprising:

- a) a liposome having an antineoplastic drug encapsulated therein; and
- b) an empty liposome, wherein said antineoplastic drug is a vinca

alkaloid.

11. (Original) The liposomal formulation of claim 10, wherein said vinca

alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

12. (Original) The liposomal formulation of claim 11, wherein said vinca alkaloid is vincristine.

13. (Original) The liposomal formulation of claim 11, wherein said vinca alkaloid is vinorelbine.

14-16. (Canceled)

17. (Currently Amended) A liposomal formulation comprising:

- a) a liposome having an active agent encapsulated therein; and
- b) an empty liposome,

wherein at least 50% of said active agent comprises free active agent and precipitated active agent is precipitated in said liposomes.

18-21. (Canceled)

22. (Previously Presented) The liposomal formulation of claim 17, wherein said active agent is an antineoplastic drug.

23. (Previously Presented) The liposomal formulation of claim 22, wherein said antineoplastic drug is a camptothecin.

24. (Previously Presented) The liposomal formulation of claim 23, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

25. (Previously Presented) The liposomal formulation of claim 24, wherein said camptothecin is topotecan.

26. (Previously Presented) The liposomal formulation of claim 22, wherein said antineoplastic drug is a vinca alkaloid.

27. (Previously Presented) The liposomal formulation of claim 26, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

28. (Previously Presented) The liposomal formulation of claim 27, wherein said vinca alkaloid is vincristine.

29. (Previously Presented) The liposomal formulation of claim 27, wherein said vinca alkaloid is vinorelbine.